High expression of CLDN17 was observed in 53.8% (28/52) of HCC tissues 30.0% (3/10) of non-neoplastic cirrhosis tissues, 40.0% (4/10) of histologically non-neoplastic tissues adjacent to the tumor and in 40.0% (12/30) of hepatic tissues (P = 0.0001 < 0.001) (Table 1). This evidence concerns the gene CLDN17 and hepatocellular carcinoma.